BioCentury | Aug 6, 2020
Finance

‘Not drip-feeding’: Andera looks to deploy record €450M fund to mostly European biotechs

...largest fund to date at €450 million. Andera Partners’ Olivier Litzka said the firm anticipates Biodiscovery...
...not always doing it the cheap way, but doing it the right way,” said Litzka. Biodiscovery...
...last fund, Biodiscovery 5, closed in February 2018 at €345 million ($428 million). Litzka said Biodiscovery...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...use to present antibiotic resistance Infectious, inflammation Crescendo Biologics Ltd. $69.1 Series B Andera Partners, Biodiscovery...
...million ($428 million) for its BioDiscovery 5 Fund, an 80% jump from the 2013 vintage BioDiscovery...
BioCentury | Feb 16, 2019
Finance

Andera looks early for cancer immunotherapy

...in the founding team was important.” Raphaël Wisniewski, Andera Andera's Raphaël Wisniewski said the firm’s BioDiscovery...
...Zipkin, Staff Writer Andera Partners Grey Wolf Therapeutics Endoplasmic reticulum aminopeptidase 1 (ERAP1) (ARTS1) (ERAAP) Endoplasmic reticulum aminopeptidase 2 (ERAP2) BioDiscovery...
BioCentury | Jan 18, 2019
Product R&D

Modality moves at Vertex

...million in series A funding, a paper highlighting a novel CRISPR enzyme, and a novel biodiscovery...
...and offer different editing properties from Cas9 (see “Cutting Edge Diagnostics” ). Using its protein biodiscovery...
BioCentury | Jul 6, 2018
Finance

Dynacure’s quick transfer

...can provide significant capital in the future. Andera is investing its €345 million ($428 million) BioDiscovery...
BioCentury | May 18, 2018
Finance

China comes to Europe

...large new funds. In February, Andera Partners (formerly Edmond de Rothschild Investment Partners) closed its BioDiscovery...
BioCentury | Apr 13, 2018
Financial News

Rothschild becomes Andera after employee, partner buyout

...buyout will not affect the firm's life science investment strategy. In February, EdRIP closed the BioDiscovery...
BioCentury | Apr 6, 2018
Financial News

Partners, employees buy out Rothschilds' stake in EdRIP

...buyout will not affect the firm's life science investment strategy. In February, EdRIP closed the BioDiscovery...
BioCentury | Mar 15, 2018
Company News

Arbor launches with $15.6 million, new CRISPR enzyme

...it will pursue therapeutic or diagnostic applications with Cas13d. The company's primary focus is on biodiscovery...
BioCentury | Feb 6, 2018
Financial News

EdRIP unveils new €345 million fund

...Edmond de Rothschild Investment Partners closed its fifth fund, BioDiscovery 5, at €345 million ($428 million...
...shy of the revised hard cap of €350 million ($434.2 million). The firm’s previous fund, BioDiscovery...
Items per page:
1 - 10 of 62
BioCentury | Aug 6, 2020
Finance

‘Not drip-feeding’: Andera looks to deploy record €450M fund to mostly European biotechs

...largest fund to date at €450 million. Andera Partners’ Olivier Litzka said the firm anticipates Biodiscovery...
...not always doing it the cheap way, but doing it the right way,” said Litzka. Biodiscovery...
...last fund, Biodiscovery 5, closed in February 2018 at €345 million ($428 million). Litzka said Biodiscovery...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...use to present antibiotic resistance Infectious, inflammation Crescendo Biologics Ltd. $69.1 Series B Andera Partners, Biodiscovery...
...million ($428 million) for its BioDiscovery 5 Fund, an 80% jump from the 2013 vintage BioDiscovery...
BioCentury | Feb 16, 2019
Finance

Andera looks early for cancer immunotherapy

...in the founding team was important.” Raphaël Wisniewski, Andera Andera's Raphaël Wisniewski said the firm’s BioDiscovery...
...Zipkin, Staff Writer Andera Partners Grey Wolf Therapeutics Endoplasmic reticulum aminopeptidase 1 (ERAP1) (ARTS1) (ERAAP) Endoplasmic reticulum aminopeptidase 2 (ERAP2) BioDiscovery...
BioCentury | Jan 18, 2019
Product R&D

Modality moves at Vertex

...million in series A funding, a paper highlighting a novel CRISPR enzyme, and a novel biodiscovery...
...and offer different editing properties from Cas9 (see “Cutting Edge Diagnostics” ). Using its protein biodiscovery...
BioCentury | Jul 6, 2018
Finance

Dynacure’s quick transfer

...can provide significant capital in the future. Andera is investing its €345 million ($428 million) BioDiscovery...
BioCentury | May 18, 2018
Finance

China comes to Europe

...large new funds. In February, Andera Partners (formerly Edmond de Rothschild Investment Partners) closed its BioDiscovery...
BioCentury | Apr 13, 2018
Financial News

Rothschild becomes Andera after employee, partner buyout

...buyout will not affect the firm's life science investment strategy. In February, EdRIP closed the BioDiscovery...
BioCentury | Apr 6, 2018
Financial News

Partners, employees buy out Rothschilds' stake in EdRIP

...buyout will not affect the firm's life science investment strategy. In February, EdRIP closed the BioDiscovery...
BioCentury | Mar 15, 2018
Company News

Arbor launches with $15.6 million, new CRISPR enzyme

...it will pursue therapeutic or diagnostic applications with Cas13d. The company's primary focus is on biodiscovery...
BioCentury | Feb 6, 2018
Financial News

EdRIP unveils new €345 million fund

...Edmond de Rothschild Investment Partners closed its fifth fund, BioDiscovery 5, at €345 million ($428 million...
...shy of the revised hard cap of €350 million ($434.2 million). The firm’s previous fund, BioDiscovery...
Items per page:
1 - 10 of 62